Gao, Wei
Muston, Dominic http://orcid.org/0000-0003-4876-7940
Monberg, Matthew
McLaurin, Kimmie
Hettle, Robert
Szamreta, Elizabeth
Swallow, Elyse
Zhang, Su
Kalemaj, Iden
Signorovitch, James
McQueen, R. Brett http://orcid.org/0000-0002-4302-2678
Funding for this research was provided by:
AstraZeneca Schweiz
Merck Sharp and Dohme
Article History
First Online: 14 August 2020
Declarations
:
: Two investigators (WG and RBM) performed the initial search and reviewed each article for quality using the QHES tool. If the quantitative score differed between reviewers, all co-authors (DM, MM, KM, RH, ES, ES, SZ, IK, and JS) discussed the score in order to reach a consensus. WG and RBM prepared the first draft of the manuscript. DM, MM, KM, RH, ES, ES, SZ, IK, and JS provided written text in the manuscript and edited all versions of the manuscript.
: This study was supported by AstraZeneca and Merck Sharp & Dohme Corp (MSD), a subsidiary of Merck & Co, Inc, Kenilworth, NJ, USA. Dominic Muston, Matthew Monberg, and Elizabeth Szamreta are employees of Merck & Co., Inc.; Wei Gao, Elyse Swallow, Su Zhang, Iden Kalemaj, and James Signorovitch are employees of Analysis Group; and Kimmie McLaurin and Robert Hettle are employees of AstraZeneca. Robert Brett McQueen received consulting fees from Analysis Group to develop recommendations for cost-effectiveness studies of PARP inhibitors in advanced ovarian cancer.
: Please see Appendix 1, Appendix 2, and Appendix 3 in the Electronic Supplementary Material for the search strategy inclusion criteria, and the full data extraction grid.